AIMS/HYPOTHESIS: Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. METHODS: The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes randomly allocated to intensive or standard glucose control in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Rates were calculated by 5 year baseline age (or age at diagnosis) and diabetes duration strata. Risks were estimated using Cox models adjusted for treatment assignment and HbA1c. RESULTS: The mean age (±SD) was 65.8 ± 6.4 years, age at diagnosis was 57.8 ± 8.7 years and diabetes duration was 7.9 ± 6.4 years. Diabetes duration was associated with the risk of macrovascular events (HR 1.13 [95% CI 1.08, 1.17]), microvascular events (1.28 [1.23, 1.33]) and death (1.15 [1.10, 1.20]) whereas age (or age at diagnosis) was only associated with the risk of macrovascular events (1.33 [1.27, 1.39]) and death (1.56 [1.48, 1.64]). No interaction was observed between diabetes duration, age and the risk of macrovascular events or death (both p > 0.4). However, an interaction was observed between diabetes duration, age and the risk of microvascular events (p = 0.002), such that the effects of increasing diabetes duration were greatest at younger rather than older age. CONCLUSIONS/ INTERPRETATION: In patients with type 2 diabetes, age or age at diagnosis and diabetes duration are independently associated with macrovascular events and death whereas only diabetes duration is independently associated with microvascular events and this effect is greater in the youngest patients.
AIMS/HYPOTHESIS: Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. METHODS: The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes randomly allocated to intensive or standard glucose control in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Rates were calculated by 5 year baseline age (or age at diagnosis) and diabetes duration strata. Risks were estimated using Cox models adjusted for treatment assignment and HbA1c. RESULTS: The mean age (±SD) was 65.8 ± 6.4 years, age at diagnosis was 57.8 ± 8.7 years and diabetes duration was 7.9 ± 6.4 years. Diabetes duration was associated with the risk of macrovascular events (HR 1.13 [95% CI 1.08, 1.17]), microvascular events (1.28 [1.23, 1.33]) and death (1.15 [1.10, 1.20]) whereas age (or age at diagnosis) was only associated with the risk of macrovascular events (1.33 [1.27, 1.39]) and death (1.56 [1.48, 1.64]). No interaction was observed between diabetes duration, age and the risk of macrovascular events or death (both p > 0.4). However, an interaction was observed between diabetes duration, age and the risk of microvascular events (p = 0.002), such that the effects of increasing diabetes duration were greatest at younger rather than older age. CONCLUSIONS/ INTERPRETATION: In patients with type 2 diabetes, age or age at diagnosis and diabetes duration are independently associated with macrovascular events and death whereas only diabetes duration is independently associated with microvascular events and this effect is greater in the youngest patients.
Authors: M M Gabir; R L Hanson; D Dabelea; G Imperatore; J Roumain; P H Bennett; W C Knowler Journal: Diabetes Care Date: 2000-08 Impact factor: 19.112
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Kenneth C Copeland; Philip Zeitler; Mitchell Geffner; Cindy Guandalini; Janine Higgins; Kathryn Hirst; Francine R Kaufman; Barbara Linder; Santica Marcovina; Paul McGuigan; Laura Pyle; William Tamborlane; Steven Willi Journal: J Clin Endocrinol Metab Date: 2010-10-20 Impact factor: 5.958
Authors: Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams Journal: Lancet Date: 2007-09-08 Impact factor: 79.321
Authors: Gitanjali M Singh; Goodarz Danaei; Farshad Farzadfar; Gretchen A Stevens; Mark Woodward; David Wormser; Stephen Kaptoge; Gary Whitlock; Qing Qiao; Sarah Lewington; Emanuele Di Angelantonio; Stephen Vander Hoorn; Carlene M M Lawes; Mohammed K Ali; Dariush Mozaffarian; Majid Ezzati Journal: PLoS One Date: 2013-07-30 Impact factor: 3.240
Authors: Matthew J O'Brien; Susan L Karam; Amisha Wallia; Raymond H Kang; Andrew J Cooper; Nicola Lancki; Margaret R Moran; David T Liss; Theodore A Prospect; Ronald T Ackermann Journal: JAMA Netw Open Date: 2018-12-07
Authors: Megan M Schellinger; Mary Pell Abernathy; Barbara Amerman; Carissa May; Leslie A Foxlow; Amy L Carter; Kelli Barbour; Erin Luebbehusen; Katherine Ayo; Dina Bastawros; Rebecca S Rose; David M Haas Journal: Matern Child Health J Date: 2017-02
Authors: Justin B Echouffo-Tcheugui; Teemu J Niiranen; Elizabeth L McCabe; Mir Henglin; Mohit Jain; Ramachandran S Vasan; Martin G Larson; Susan Cheng Journal: Diabetes Care Date: 2020-10-08 Impact factor: 19.112